

GALECTIN THERAPEUTICS INC

Form 3

September 24, 2014

**FORM 3 UNITED STATES SECURITIES AND EXCHANGE COMMISSION**

Washington, D.C. 20549

OMB APPROVAL

OMB Number: 3235-0104

Expires: January 31, 2005

Estimated average burden hours per response... 0.5

**INITIAL STATEMENT OF BENEFICIAL OWNERSHIP OF SECURITIES**

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934,  
Section 17(a) of the Public Utility Holding Company Act of 1935 or Section  
30(h) of the Investment Company Act of 1940

(Print or Type Responses)

1. Name and Address of Reporting Person \*

Â OMENN GILBERT S

(Last)

(First)

(Middle)

2. Date of Event Requiring Statement

(Month/Day/Year)

09/23/2014

3. Issuer Name and Ticker or Trading Symbol

GALECTIN THERAPEUTICS INC [GALT]

4. Relationship of Reporting Person(s) to Issuer

5. If Amendment, Date Original Filed(Month/Day/Year)

(Check all applicable)

☒ Director ☐ 10% Owner☐ Officer ☐ Other  
(give title below) (specify below)C/O GALECTIN  
THERAPEUTICS INC.,Â 4960  
PEACHTREE INDUSTRIAL  
BLVD. SUITE 240

(Street)

NORCROSS,Â GAÂ 30071

(City)

(State)

(Zip)

6. Individual or Joint/Group

Filing(Check Applicable Line)

☒ Form filed by One Reporting Person☐ Form filed by More than One Reporting Person**Table I - Non-Derivative Securities Beneficially Owned**1. Title of Security  
(Instr. 4)2. Amount of Securities Beneficially Owned  
(Instr. 4)3. Ownership Form:  
Direct (D)  
or Indirect (I)  
(Instr. 5)4. Nature of Indirect Beneficial Ownership  
(Instr. 5)

Common Stock

25,009

D

Â

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

SEC 1473 (7-02)

**Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB control number.**

**Table II - Derivative Securities Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)**1. Title of Derivative Security  
(Instr. 4)2. Date Exercisable and Expiration Date  
(Month/Day/Year)

3. Title and Amount of Securities Underlying Derivative Security

4. Conversion or Exercise

5. Ownership Form of

6. Nature of Indirect Beneficial Ownership  
(Instr. 5)

# Edgar Filing: GALECTIN THERAPEUTICS INC - Form 3

| Date<br>Exercisable                         | Expiration<br>Date | (Instr. 4) |                 | Amount or<br>Number of<br>Shares | Price of<br>Derivative<br>Security | Derivative<br>Security:<br>Direct (D)<br>or Indirect<br>(I)<br>(Instr. 5) |   |
|---------------------------------------------|--------------------|------------|-----------------|----------------------------------|------------------------------------|---------------------------------------------------------------------------|---|
|                                             |                    | Title      |                 |                                  |                                    |                                                                           |   |
| Series A 12% Convertible<br>Preferred Stock | Â (1)              | Â (1)      | Common<br>Stock | 50,000                           | \$ (1)                             | D                                                                         | Â |

## Reporting Owners

| Reporting Owner Name / Address                                                                                       | Relationships |           |         |       |
|----------------------------------------------------------------------------------------------------------------------|---------------|-----------|---------|-------|
|                                                                                                                      | Director      | 10% Owner | Officer | Other |
| OMENN GILBERT S<br>C/O GALECTIN THERAPEUTICS INC.<br>4960 PEACHTREE INDUSTRIAL BLVD. SUITE 240<br>NORCROSS, GA 30071 | Â X           | Â         | Â       | Â     |

## Signatures

/s/ Gilbert S.  
Omenn

09/23/2014

\*\*Signature of  
Reporting Person

Date

## Explanation of Responses:

\* If the form is filed by more than one reporting person, *see* Instruction 5(b)(v).

\*\* Intentional misstatements or omissions of facts constitute Federal Criminal Violations. *See* 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

- (1) The 50,000 shares of Series A Preferred stock are convertible into 4,167 shares of common stock at the option of the holder at any time.  
There is no expiration date on the conversion into common stock.

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, *See* Instruction 6 for procedure.

Potential persons who are to respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB number.